SCHEMBL403680

SCHEMBL403680

NOCc1cccc(Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 14/20 1.00
AGXT P21549 8/20 1.00
CYP3A4 P08684 2/20 1.00
PNMT P11086 1/20 0.59
MAOB P27338 2/20 0.58
TAAR1 Q96RJ0 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30079884 1.00 IDO1 (1.00) IDO1AGXTCYP3A4PNMTMAOB
Hydrochloric Acid SCHEMBL1715226 0.98 IDO1 (1.00) IDO1AGXTCYP3A4PNMTMAOB
SCHEMBL437710 0.84 IDO1 (0.71) IDO1AGXTCYP3A4
SCHEMBL28404628 0.82 CYP3A4 (0.69) IDO1AGXTCYP3A4PNMTMAOB
SCHEMBL10866481 0.82 CYP3A4 (0.69) IDO1AGXTCYP3A4PNMTMAOB
SCHEMBL1855225 0.80 CYP3A4 (0.67) IDO1AGXTCYP3A4PNMTMAOB
SCHEMBL1521149 0.79 AGXT (0.73) IDO1AGXTCYP3A4TAAR1
SCHEMBL4950985 0.78 CYP3A4 (0.64) IDO1AGXTCYP3A4PNMTMAOB
SCHEMBL7040986 0.78 CYP3A4 (0.64) IDO1AGXTCYP3A4PNMTMAOB
SCHEMBL7958908 0.78 CYP3A4 (0.64) IDO1AGXTCYP3A4PNMTMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661436-B2 Method for preparing 3′-o-amino-2′-deoxyribonucleoside-5′-triphosphates DNA SCRIPT SAS (FR) 2023-05-30 US claimed
EP-4126895-A1 METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES DNA Script (FR) 2023-02-08 EP claimed
CN-115362161-A Process for preparing 3' -O-amino-2 ' -deoxyribonucleoside-5 ' -triphosphates DNA斯克瑞普特公司 2022-11-18 CN claimed
WO-2021198040-A1 METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES. DNA SCRIPT (FR) 2021-10-07 WO claimed
US-20210300961-A1 METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES DNA SCRIPT SAS (FR) 2021-09-30 US claimed
EP-2697193-B1 SUBSTITUTED 5-(CYCLOHEX-2-EN-1-YL)-PENTA-2,4-DIENES AND 5-(CYCLOHEX-2-EN-1-YL)-PENT-2-EN-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS BAYER IP GMBH (DE) 2016-07-06 EP claimed
EP-2227233-B1 IDO INHIBITORS NEWLINK GENETICS (US) 2013-02-13 EP claimed
US-20110053941-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-03-03 US claimed
EP-2227233-A2 IDO INHIBITORS Newlink Genetics (US) 2010-09-15 EP claimed
WO-2009073620-A2 IDO INHIBITORS NEWLINK GENETICS (US) 2009-06-11 WO claimed
US-11661436-B2 Method for preparing 3′-o-amino-2′-deoxyribonucleoside-5′-triphosphates DNA SCRIPT SAS (FR) 2023-05-30 US disclosed
EP-4126895-A1 METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES DNA Script (FR) 2023-02-08 EP disclosed
CN-115362161-A Process for preparing 3' -O-amino-2 ' -deoxyribonucleoside-5 ' -triphosphates DNA斯克瑞普特公司 2022-11-18 CN disclosed
WO-2021198040-A1 METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES. DNA SCRIPT (FR) 2021-10-07 WO disclosed
US-20210300961-A1 METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES DNA SCRIPT SAS (FR) 2021-09-30 US disclosed
US-20110053941-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-03-03 US disclosed
US-20080234298-A1 ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER TRACON PHARMACEUTICALS, INC. (US) 2008-09-25 US disclosed
US-6562792-B1 Hygromycin derivatives PFIZER INC. 2003-05-13 US disclosed
EP-1224197-A1 HYGROMYCIN DERIVATIVES Pfizer Products Inc. (US) 2002-07-24 EP disclosed
WO-2001030795-A1 HYGROMYCIN DERIVATIVES PFIZER PRODUCTS INC. (US) 2001-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300961-A1 METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES DUT, RNMT, NUDT1 IDO1 997/4885AGXT 971/4885CYP3A4 825/4885
US-11661436-B2 Method for preparing 3′-o-amino-2′-deoxyribonucleoside-5′-triphosphates DUT, RNMT, NUDT1 IDO1 984/4885AGXT 924/4885CYP3A4 879/4885
US-20110053941-A1 IDO Inhibitors IDO1, IDO2, INMT IDO1 1/4885AGXT 365/4885CYP3A4 413/4885
US-20080234298-A1 ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER FEN1, UNG, FOLR1 IDO1 3342/4885AGXT 550/4885CYP3A4 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.